Esteemed Shareholders and Investors,
On behalf of RaQualia Pharma, Inc., I would like to express our sincere gratitude for your continued support and confidence.
Since the foundation of RaQualia Pharma, Inc. in 2008, we have been dedicated to improving patients' lives through innovative drug discovery. While drug discovery is a challenging endeavor that involves significant risks, we remain committed to pushing the boundaries of science to develop novel therapies.
Leveraging our world-class research infrastructure, we have created a number of drug candidates and successfully entered into multiple licensing agreements. These achievements underscore our strong research and development capabilities and provide a solid foundation for future growth. Our four marketed products, including tegoprazan, a gastric acid secretion inhibitor, have reached over 40 countries worldwide, including East Asia, Southeast Asia, North America, South America, and the Middle East. The royalties generated from these marketed products fuel our ongoing efforts to explore new modalities and address unmet medical needs.
Under our new management team, we are poised for even greater growth. We are committed to enhancing our investor relations activities to foster a deeper understanding of our business and to build a strong partnership with our shareholders. We will continue to provide timely disclosures of business plans and their updates, presentations, and other items. By strengthening our IR materials and enhancing our information dissemination, we aim to ensure transparent communication. We also welcome your feedback and insights, which will be invaluable as we shape our future direction.
We appreciate your continued support.
Sincerely,
President and CEO
Masaki Sudo